Help bring a first-in-class cancer therapy to patients — faster.
We've proven our SnB payload platform in the lab and secured a Dutch patent. What we need now isn't only capital — it's the right people in your network: doors to companies for joint ventures, and funding to reach the clinic.
The science is ready. The clock isn't kind.
GenLumina is building the activation layer for next-generation precision oncology — a light-activated, DNA-metal payload that overcomes resistance while sparing healthy cells. The faster we validate and partner, the faster this reaches the people who can't wait. Faster validation. Faster partnerships. Faster impact.
Three doors you can open
A 15-minute conversation is enough to point us the right way. Pick whichever fits your network.
Open a door
Introduce us to biotech & pharma companies with antibodies or peptides who could co-develop through a joint venture.
Fund the science
Connect us to investors, family offices or grant programs for the €5M round that takes us from validated to clinic-ready.
Nominate a VIP
Know someone who should see this — a decision-maker, connector or champion? Put a name forward and we'll take it from there.
Send us your antibody. We run the proof of concept — on us.
We are the “D” in ADCs and PDCs. We conjugate a validated antibody to our SnB payload and prove the potential for your indication. No payload chemistry to solve. No upfront cost.
Who in your network should know about this?
Book a short 1-on-1 to hear the story and tell us where you can help — or nominate a VIP and we'll reach out.